Home Latest Articles
Latest Articles
  • Qi ZHENG, Yun-dong GU, Yan-yun CAO, Yi RU, Xin LI, Bin LI
    World Clinical Drug. 2018, 39(2): 113-119.
    Objective

    To evaluate the clinical efficacy and safety of Bailing tablet in the treatment of vitiligo.

    Methods

    Randomized controlled trials (RCTs) for the vitiligo treatment using Bailing tablet were retrieved, and the retrieval data were due on September 5, 2017. The Meta-analysis was performed by using RevMan 5.2 software after data extraction, and the quality of the included researches were evaluated according to the Cochrane 5.0.2 manual requirements. The outcome indicators were expressed in relative risk (RR), 95% confidence interval (CI) and P values.

    Results

    Total 17 RCTs were enrolled. The quality of the included researches were low. The results of data analysis showed that the total effective rate of experiment group [Bailing tablet combined with traditional Chinese medicine or narrow spectrum medium wave ultraviolet (NB-UVB)] was significantly better than that of control group (traditional Chinese medicine or NB-UVB)[RR=1.33, 95% CI (1.07, 1.67), P=0.01]. Because of the different interventions of control group, we conducted subgroup analysis on the same interventions. However, the subgroup Meta analysis results showed that the total effective rate of using Bailing tablet alone in the treatment of vitiligo was markedly lower than the Chinese traditional medicine group, the NB-UVB group and the combination group of Bailing tablet or the traditional Chinese medicine and western medicine ointment [RR=0.65, 95%CI (0.57, 0.75),P<0.000 01]. The corresponding outcome indicators respectively were [RR=0.63, 95%CI (0.51, 0.79),P < 0.000 01], [RR=0.72, 95% CI (0.61, 0.84), P < 0.000 1] and [RR=0.63, 95% CI (0.51, 0.78), P < 0.000 1).

    Conclusion

    Bailing tablet has certain therapeutic effect on vitiligo treatment and no serious adverse reactions. However, Bailing tablet should be used as combination with other treatments.

  • Ji-shuo LIU, Mian-li PAN, Han HU, Yi LIU, Long-hai SHEN
    World Clinical Drug. 2018, 39(2): 120-124.
    Objective

    To explore the anti-aging effect of Yiling wine on model of D-galactose-induced aging mice.

    Methods

    The other groups except the control group were establish the model of D-galactose-induced aging mice, all mice were randomly divided into control group, model group, vitamin E group, 2% and 5% each dose Yiling wine group. Obseving and collecting mice serum samples for biochemical indicators of superoxide dismutase (SOD), malondialdehyde (MDA), catalase (CAT), and total antioxidant capacity (T-AOC). Meanwhile, the effect of improving learning and memory abilities were investigated through the Morris water maze test.

    Results

    In Morris water maze test, there was no significant difference in swimming distance of the mice in each group (P>0.05). But compared with the control group, times that mice across the platform of model group were decreased, different doses of 2% Yiling wine and vitamin E groups increased the frequency of crossing the original platform, but there were no significant differences (P>0.05); Compared with the model group, spleen index in vitamin E group, 2% and 5% high dose Yiling wine groups were higher, the differences were statistical significance (P<0.01). Compared with the control group, model group decreased the levels of serum CAT and T-AOC but increased MDA level (P<0.05 or P<0.01); After intragastric administration of Yiling wine, compared with model group, the levels of serum MDA were decreased in 2% high dose Yiling wine group and 5% Yiling wine in each dose group, the level of serum T-AOC was increased in 2% high dose Yiling wine group, the levels of serum SOD and CAT were increased in 2% and 5% Yiling wine in each dose group, and the differences were statistically significant (P<0.05 or P<0.01).

    Conclusion

    Yiling wine can improve the antioxidant capacity and immunity in D-galactose-induced aging mice, it can also improve their antioxidant capacity and immunity, it has a certain effect on retarding aging.

  • Nian WANG, Na Li, Shuai YAN, Li ZHAO, Yu-fan WANG, Yong-de PENG
    World Clinical Drug. 2018, 39(2): 125-129.
  • You-heng FENG, Ji-yuan WANG, Liu-ge GU, Yan QIN
    World Clinical Drug. 2018, 39(2): 130-134.
    Objective

    To study the inhibitory effect of HY152-J against artificial restructured human liver microsomal CYP450 enzymes in vitro.

    Methods

    The method of single substrate CYP450 enzyme probe was used to study the inhibitory effect of HY152-J, and the metabolites of the precipitated samples for each probe were analyzed by LC-MS/MS. The concentration of metabolites was assayed to calculate the IC50 for inhibitory potency evaluation.

    Results

    The residual activities of CYP3A4 (6β-hydroxytestosterone), CYP3A4 (1-hydroxymidazolam), CYP2C19 (4-hydroxymephenytoin), CYP2D6 (dextrophan), CYP1A2 (acetaminophen) and CYP2C9 (4-hydroxydiclofenac) were analyzed as 4.6%, 0.6%, 0.3%, 8.1%, 32.5% and 15.3% respectively, and the IC50 values were 21.02, 2.66, 1.23,14.9, 71.0 and 35.8 μmol/L.

    Conclusion

    The inhibitory effects of HY152-J on CYP3A4 (1-hydroxymidazolam), CYP2C19 are moderate inhibition,and the effects on CYP3A4 (6β-hydroxytestosterone), CYP2D6, CYP1A2 and CYP2C9 are very few effections.

  • Chang-feng CHAI, Xiao-ying BI
    World Clinical Drug. 2018, 39(2): 135-141.

    Valproate is widely used in the treatment of epilepsy. Recently, the pharmacogenetics studies have showed that some genes could affect the pharmacokinetics of valproate. This review describes the pharmacogenomics of valproate and its research directions.

  • Yi-wen YANG, Lei-hong XIANG, Cheng-feng ZHANG
    World Clinical Drug. 2018, 39(2): 142-144.

    Vitiligo is a common skin depigmentation disease without effective treatment. Currently, the major treatments include drug treatment, phototherapy, bleaching, covering therapy and surgical treatment. This review describes commonly used drug therapies for vitiligo and the new drug research progress for vitiligo.

  • Shan MAO, Wei GU
    World Clinical Drug. 2018, 39(1): S1-S4.

    This article describes the concept and connotation of chronic respiratory disease, and then analyzes the problems and characteristics of Chinese chronic respiratory disease management in depth. Combined with Chinese national conditions, this paper puts forward the construction of Chinese characteristics with chronic respiratory disease management model in aims to improve the prevention and treatment of chronic respiratory disease in China.

  • Dan-yang ZHOU, Shan MAO
    World Clinical Drug. 2018, 39(1): 1-5.

    The 2017 global initiative for chronic obstructive pulmonary disease (GOLD) has been fully revised in the diagnosis, evaluation and management of chronic obstructive pulmonary disease (COPD) based on the updated comprehensive references. It was issued on November 16th 2016, which was world COPD day. This article interprets the key points of clinic issue in 2017 edition of GOLD reports.

  • Ying SHI, Wei GU
    World Clinical Drug. 2018, 39(1): 6-8.

    The clinical treatment of chronic obstructive pulmonary disease (COPD) has achieve a great progress in recent years. However, regarding to the use of glucocorticoids is still an important issue. Recent clinical studies on eosinophils in COPD have found that the COPD patients with eosinophilia can benefit from glucocorticoids. This review provides a reference for COPD’s clinical diagnosis and its treatment.

  • Jing ZHANG, Shan MAO
    World Clinical Drug. 2018, 39(1): 9-13.

    For bronchial asthma, there are relatively detailed clinical guidelines. However, the clinical attention should be paid to the diagnosis and treatment of the various types of low incidence asthma. This review describes the special type asthma of eight categories, including their definition, pathogenesis, diagnosis and therapy, and provides a reference for clinical doctors.

News